journal article·2022-10

Yield‐Stress and Creep Control Depot Formation and Persistence of Injectable Hydrogels Following Subcutaneous Administration

Carolyn K. Jons, Abigail K. Grosskopf, Julie Baillet, Jerry Yan, John H. Klich, Olivia M. Saouaf, Eric A. Appel

Advanced Functional Materials· Volume 32· Issue 40
Publisher page

Abstract

Abstract Hydrogels that can be injected into the body using standard needles or catheters enable a minimally invasive strategy to prolong local delivery of therapeutic cargo. In particular, physically cross‐linked hydrogels exhibit shear‐thinning and self‐healing behaviors enabling facile injectability and depot formation upon administration. While prior efforts to characterize these systems have focused on injectability and cargo release behaviors, prediction of cargo release in the body often assumes these materials form a depot rather than spreading out upon administration. Here, it is evaluated how hydrogel rheology correlates with depot formation and persistence following subcutaneous administration in mice with two physiochemically distinct, physically cross‐linked hydrogel systems. Calcium‐alginate and polymer‐nanoparticle hydrogel systems exhibit variable mechanical behaviors across several rheological properties (stiffness, viscoelasticity, yield stress, and creep). By relating measured rheological properties to depot formation and persistence time following subcutaneous administration, it is identified that yield stress is predictive of initial depot formation while creep is predictive of depot persistence for these two gel systems. Indeed, only materials with yield stresses >25 Pa form robust depots, and reduced creep correlates with longer depot persistence. These findings provide predictive insights into design considerations for hydrogel technologies capable of extended controlled release of therapeutic cargo.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Blood properties and coagulation · Botulinum Toxin and Related Neurological Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Materials Science & Engineering Stanford University Stanford CA 94305 USA

Department of Chemical Engineering Stanford University Stanford CA 94305 USA

CNRS, Bordeaux INP, LCPO University of Bordeaux Pessac 33600 France

Department of Bioengineering Stanford University Stanford CA 94305 USA

Stanford ChEM‐H Institute Stanford University Stanford CA 94305 USA

Woods Institute for the Environment Stanford University Stanford CA 94305 USA

Department of Pediatrics Endocrinology Stanford University School of Medicine Stanford CA 94305 USA

Funding

American Cancer Society

References (54)

Show source-provided references
1. In Pharmaceutical Drug Delivery Market by Route of Administration Application Facility of Use COVID‐19 Impact – Global Forecast to 2026 2021.
2. 10.1177/088532821668034310.1177/0885328216680343 ↗
3. 10.1016/j.jconrel.2014.02.00110.1016/j.jconrel.2014.02.001 ↗
4. 10.1021/bm501520610.1021/bm5015206 ↗
5. 10.1002/adfm.20190278510.1002/adfm.201902785 ↗
6. 10.1016/j.scib.2020.04.01210.1016/j.scib.2020.04.012 ↗
7. 10.1016/j.jvs.2007.09.00510.1016/j.jvs.2007.09.005 ↗
8. 10.1038/s41551-019-0442-z10.1038/s41551-019-0442-z ↗
9. 10.1038/nri.2017.8910.1038/nri.2017.89 ↗
10. 10.1002/bit.2236110.1002/bit.22361 ↗
11. 10.1016/S0168-3659(99)00138-810.1016/S0168-3659(99)00138-8 ↗
12. 10.12968/jowc.2006.15.7.2692910.12968/jowc.2006.15.7.26929 ↗
13. 10.1016/j.ijbiomac.2015.07.03710.1016/j.ijbiomac.2015.07.037 ↗
14. 10.1080/08941939927264710.1080/089419399272647 ↗
15. 10.1016/j.biotechadv.2011.01.00510.1016/j.biotechadv.2011.01.005 ↗
16. 10.3109/10837450.2011.60999210.3109/10837450.2011.609992 ↗
17. Li J. Y. · Nat. Rev. Mater. · 2016 · 1 · 1601
18. 10.1016/S0939-6411(00)00090-410.1016/S0939-6411(00)00090-4 ↗
19. 10.1002/adma.20080210610.1002/adma.200802106 ↗
20. 10.1039/c2cs15296g10.1039/c2cs15296g ↗
21. 10.1016/j.cell.2019.04.01210.1016/j.cell.2019.04.012 ↗
22. 10.1038/s41578-021-00372-210.1038/s41578-021-00372-2 ↗
23. 10.1021/acs.chemrev.0c0117710.1021/acs.chemrev.0c01177 ↗
24. 10.1002/mabi.20200029510.1002/mabi.202000295 ↗
25. 10.1039/C7BM00780A10.1039/C7BM00780A ↗
26. 10.1038/nmat447410.1038/nmat4474 ↗
27. 10.1038/s41598-017-06311-y10.1038/s41598-017-06311-y ↗
28. 10.1023/B:PHAM.0000022403.60314.5110.1023/B:PHAM.0000022403.60314.51 ↗
29. 10.1177/19322968130070012810.1177/193229681300700128 ↗
30. 10.3390/pharmaceutics1306086410.3390/pharmaceutics13060864 ↗
31. 10.1016/0168-3659(87)90034-410.1016/0168-3659(87)90034-4 ↗
32. 10.1038/s41467-021-21024-710.1038/s41467-021-21024-7 ↗
33. 10.1038/ncomms729510.1038/ncomms7295 ↗
34. 10.1039/C9ME00120D10.1039/C9ME00120D ↗
35. 10.1021/acscentsci.0c0073210.1021/acscentsci.0c00732 ↗
36. 10.1002/btm2.1014710.1002/btm2.10147 ↗
37. 10.1073/pnas.190785511610.1073/pnas.1907855116 ↗
38. 10.1021/acsbiomaterials.0c0130610.1021/acsbiomaterials.0c01306 ↗
39. 10.1186/s13036-020-0227-710.1186/s13036-020-0227-7 ↗
40. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
41. 10.1002/term.201110.1002/term.2011 ↗
42. 10.1016/j.ijbiomac.2017.12.13710.1016/j.ijbiomac.2017.12.137 ↗
43. Hariyadi D. M. · Adv. Pharm. Pharm. Sci. · 2020 · 2020 · 8886095
44. 10.1038/s41598-017-17286-110.1038/s41598-017-17286-1 ↗
45. 10.1002/pol.2021065210.1002/pol.20210652 ↗
46. Kong H. J. · Polymer · 2002 · 43 · 23
47. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
48. Lee H. P. · Nat. Mater. · 2017 · 16 · 12
49. 10.1023/A:101588721343110.1023/A:1015887213431 ↗
50. 10.4161/derm.2192310.4161/derm.21923 ↗
51. 10.1002/adtp.20200024210.1002/adtp.202000242 ↗
52. 10.1007/s10856-015-5423-510.1007/s10856-015-5423-5 ↗
53. Saouaf O. M. · J. Biomed. Res. · 2021 · 109 · 2173
54. 10.1126/sciadv.abn826410.1126/sciadv.abn8264 ↗